(@kkomanduri)

Goal 3: Advance Translational Research

How can we develop more selective immunosuppression for allogeneic hematopoietic cell transplantation?

Graft versus host disease (GVHD) remains the most significant complication of allogeneic hematopoietic stem cell transplantation (HCT). While the use of HCT has grown significantly safer and has demonstrated broad efficacy in the setting of a broad range of blood diseases, immunosuppressive therapy has not dramatically evolved since the introduction of calcineurin inhibitor-based approaches decades ago. The availability ...more »

Voting

106 net votes
129 up votes
23 down votes
Active
(@giralts)

Goal 3: Advance Translational Research

Can we leverage exisiting registries to perform prospective trials and advance reduce the cost of doing research?

Current costs for multicenter randomized or non randomized trials are astronomical, and a major obstacle to rapid implementation of potential lifesaving discoveries. In the field of hematopoietic cell transplantation (HCT) their is a federal mandate to have a treatment outcome registry. Funds should be made available to leverage that registry to perform prospective trials either randomized or not since HCT programs need ...more »

Voting

123 net votes
154 up votes
31 down votes
Active
(@sophpacz)

Goal 3: Advance Translational Research

Maximizing anti-tumor immunity following allogeneic HCT with biomarkers

Allogeneic hematopoietic cell transplantation (allo-HCT) is one of the most effective forms of tumor immunotherapy available to date. Allo-HCT can be life-saving for patients with aggressive malignancies that cannot be cured through other strategies. The immunotherapeutic efficacy of allo-HCT depends on donor T cell recognition of alloantigens on leukemic cells, which is known as the graft-versus-tumor effect (GVT). No ...more »

Voting

32 net votes
52 up votes
20 down votes
Active
(@lholmber)

Goal 3: Advance Translational Research

What is the best time to undergo a stem cell transplant (HCT)?

In this era of all the new therapies in cancer treatment, I believe stem cell transplants run the risk to be delegated to be used as last ditch effort to treat patients when all other therapy fails. Historically this has not been the group that benefitted the most from a transplant. I believe that better national studies need to be designed and funded to address the optimal use of transplant to benefit our patients ...more »

Voting

47 net votes
78 up votes
31 down votes
Active
(@mboeckh)

Goal 2: Reduce Human Disease

Optimize vaccine responses in HCT recipients and patients with hematologic malignancies

Vaccination responses are poor early after hematopoietic cell transplantation and in the context of cytotoxic chemotherapy. To design effective vaccination strategies it is critical to understand the immune correlates of protection. There is a need to study strategies to study and improve vaccine efficacy in this growing population of immunosuppressed individuals that is increasingly of advanced age.

Voting

15 net votes
25 up votes
10 down votes
Active
(@james.ferrara)

Goal 2: Reduce Human Disease

Personalized therapy of HCT complications

Can biomarkers make all the use of new predictive biomarkers enable earlier and more effective treatment of acute GVHD? Can biomarkers accurately guide reduction in therapy for patients who will respond to standard steroid treatment? Can biomarkers enable earlier and thus more effective therapy for high risk GVHD? Can new biomarkers (proteomic, genomic or a combination) also predict patients who are risk of relapse?

Voting

74 net votes
99 up votes
25 down votes
Active
(@giralts)

Goal 2: Reduce Human Disease

What are the mechanisms of lung injury after HCT

Despite major advances in supportive care and tissue typing non relapse mortality rates for adults undergoing hematopoietic cell transplantation are still between 15-20 % at 2 years. Lung injury and respiratory failure is a major causes of death after HCT. Although the BMT-CTN has a focused agenda on GVHD, reduction of lung toxicities will be important to improve outcomes. NHLBI should encourage researched from the ...more »

Voting

59 net votes
88 up votes
29 down votes
Active
(@aartz0)

Goal 2: Reduce Human Disease

Transplant to Cure Older Adults with Hematologic Malignancy-Removing the Blindfold

While transplant for patients 60 and older for high-risk hematologic malignancies has increased and observational data are promising, the risks and benefits of translant versus non-transplant remain largely unknown. We now have the tools and mechanisms to remove the blindfold! The NHLBI should support the cooperative groups in conjunction with the BMT-CTN to establish a common framework for transplant trials in older ...more »

Voting

20 net votes
36 up votes
16 down votes
Active